n.毛霉（菌）病

Mucormycosis is a rare but life-threatening fungal infection, primarily affecting immunocompromised individuals.
The diagnosis of mucormycosis often requires a tissue biopsy and laboratory examination for the fungus.
Early recognition and prompt antifungal therapy are crucial in managing mucormycosis to improve patient outcomes.
Mucormycosis can manifest as rhinocerebral, disseminated, or cutaneous disease, causing severe tissue damage.
Invasive pulmonary mucormycosis (IPM) is a common presentation, particularly among those with diabetes and respiratory infections.
Treatment typically involves amphotericin B deoxycholate, lipid-based formulations, or newer echinocandins, in combination with surgical intervention.
The mortality rate from mucormycosis ranges from 30% to 50%, highlighting its urgent need for effective management.
Prevention strategies include proper wound care, controlling blood sugar levels, and avoiding exposure to contaminated environments.
Prompt referral to a specialist for suspected mucormycosis cases is vital to ensure timely and appropriate care.
Researchers continue to investigate new diagnostic tools and treatment options to combat this challenging fungal infection.
黏孢子菌病是一种罕见但可能致命的真菌感染，主要影响免疫力低下的人群。
对黏孢子菌病的确诊通常需要组织活检和实验室检查以寻找真菌。
早期识别和及时抗真菌治疗对于管理黏孢子菌病并改善患者预后至关重要。
黏孢子菌病可以表现为鼻脑型、播散型或皮肤型，导致严重的组织损伤。
入侵性肺黏孢子菌病（IPM）是常见表现，特别是在糖尿病和呼吸道感染者中。
治疗通常包括阿米卡星脱氧胆酸盐、脂质基质制剂或新型棘白菌素，结合手术干预。
黏孢子菌病的死亡率可高达30%至50%，强调了对有效管理的迫切需求。
预防策略包括正确伤口护理、控制血糖水平以及避免接触受污染环境。
对疑似黏孢子菌病的患者应迅速转诊给专科医生，以确保及时和适当的治疗。
研究人员继续研究新的诊断工具和治疗选择，以应对这一极具挑战性的真菌感染。